OneAscent Wealth Management LLC Increases Holdings in Bristol-Myers Squibb (NYSE:BMY)

OneAscent Wealth Management LLC increased its position in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 5.0% in the first quarter, according to its most recent filing with the SEC. The firm owned 5,992 shares of the biopharmaceutical company’s stock after acquiring an additional 288 shares during the period. OneAscent Wealth Management LLC’s holdings in Bristol-Myers Squibb were worth $325,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have recently made changes to their positions in BMY. Northwest Financial Advisors purchased a new position in shares of Bristol-Myers Squibb in the fourth quarter valued at about $27,000. Pacific Capital Wealth Advisors Inc. purchased a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at approximately $34,000. Turtle Creek Wealth Advisors LLC acquired a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at about $40,000. Wetzel Investment Advisors Inc. purchased a new position in shares of Bristol-Myers Squibb in the fourth quarter valued at about $40,000. Finally, Fairman Group LLC acquired a new position in shares of Bristol-Myers Squibb in the fourth quarter valued at about $42,000. Hedge funds and other institutional investors own 76.41% of the company’s shares.

Bristol-Myers Squibb Price Performance

NYSE BMY opened at $41.53 on Friday. The company has a debt-to-equity ratio of 2.99, a current ratio of 1.11, and a quick ratio of 0.99. The stock has a market cap of $84.19 billion, a price-to-earnings ratio of -13.40, a PEG ratio of 14.20 and a beta of 0.43. Bristol-Myers Squibb has a 1-year low of $39.63 and a 1-year high of $65.38. The company’s fifty day moving average price is $42.97 and its 200 day moving average price is $48.14.

Bristol-Myers Squibb (NYSE:BMY – Get Your Free Report ) last issued its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, topping the consensus estimate of ($4.53) by $0.13. The firm had revenue of $11.87 billion during the quarter, compared to analyst estimates of $11.45 billion. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. Bristol-Myers Squibb’s revenue rose 4.7% year over year. During the same period in the previous year, the business posted EPS of $2.05. On average, equities analysts forecast that Bristol-Myers Squibb will post 0.58 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, August 1st. Stockholders of record on Friday, July 5th will be given a $0.60 dividend. The ex-dividend date is Friday, July 5. This represents an annualized dividend of $2.40 and a dividend yield of 5.78%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -77.42%.

Analysts set new price targets

A number of analysts recently commented on the company. Barclays decreased their price target on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a research report on Friday, April 26th. William Blair reissued a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. BMO Capital Markets dropped their target price on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research report on Friday, April 26th. Societe Generale cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. Finally, StockNews.com cut Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Thursday. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $60.00, according to MarketBeat.com.

Check out our latest research report on BMY

Bristol-Myers Squibb profile

(Free Report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic and neuroscience. The company’s products include Eliquis for reducing the risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anticancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

See also

Get news and reviews for Bristol-Myers Squibb Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bristol-Myers Squibb and related companies with MarketBeat.com’s FREE daily email newsletter.